ArticleBMC psychiatry2025
The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence on treatment for adolescent with schizophrenia in China is limited. Understanding the current practice of antipsychotics utilization is imperative to inform appropriate use in this population.
methodsThis retrospective cohort study used electronic medical records (2018-2022) from two hospitals in China. Adolescents (12-17y) with schizophrenia (ICD-10: F20.x) who were prescribed oral antipsychotics during the study period were included. Index date was the date of the first antipsychotics prescription. Patients were followed up until the earliest of last antipsychotics prescription, 18y, or study end. Antipsychotic utilization was described by commonly prescribed antipsychotics, polypharmacy, dosage and medication adherence (indicated by proportion of days covered [PDC]). Dosage was converted using defined daily dose(DDD) for unified measurement.
resultsOverall, 869 (mean age: 15.6y, male 50.6%) and 618 (mean age: 16.1y, male 50.7%) patients were included in PKU6H and XJH, respectively. Most patients (99.65% and 100.00%) had ever used second-generation antipsychotics (SGAs), while relatively few (4.14% and 4.21%) had ever used first-generation antipsychotics (FGAs). The top three ever-prescribed SGAs were aripiprazole (50.46%), olanzapine (38.45%), risperidone (34.41%) in PKU6H, and aripiprazole (35.76%), risperidone (28.96%), paliperidone (27.83%) in XJH, 32.34% and 11.49% patients had polypharmacy, respectively. The average daily dose was 0.77(SD 0.40) DDDs and 1.00(SD 0.52) DDDs, respectively, with most (81.59% and 63.27%) ≤ 1 DDD. Medication adherence was both around 0.8 and observed with a steady trend over long-term.
conclusionsIn Chinese adolescent patients, SGA is the mainstream mostly prescribed as monotherapy. Polypharmacy is observed with a steady pattern. Antipsychotics were prescribed with equal or reduced dose compared to adults DDD, and good adherence observed. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.